Helping people with prediabetes and obesity improve their health
Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics
This study is testing different affordable treatments to help people with prediabetes and obesity lower their blood sugar and lose weight.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Texas Health Science Center at San Antonio Academic / other |
| Locations | 1 site (San Antonio, Texas) |
| Trial ID | NCT06446531 on ClinicalTrials.gov |
What this trial studies
This study aims to assist individuals with prediabetes and obesity by evaluating the effectiveness of various affordable treatments to normalize blood sugar levels and promote weight loss. Participants will be assigned to one of four groups, receiving either a combination of nutritional consultation and medication or a placebo over a six-month period. The study will involve approximately 16 visits with the research team to monitor health outcomes and metabolic changes. The ultimate goal is to identify new strategies for preventing the progression of diabetes and cardiovascular risks.
Who should consider this trial
Good fit: Ideal candidates for this study are Hispanic adults aged 18 and older with a diagnosis of prediabetes and a BMI between 25 and 40.
Not a fit: Patients who do not identify as Hispanic or those with conditions outside the specified eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide effective, affordable treatment options for managing prediabetes and obesity, potentially reducing the risk of diabetes and cardiovascular diseases.
How similar studies have performed: Other studies have shown promise in using similar approaches to manage prediabetes and obesity, indicating potential for success in this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months.
2. Age ≥ 18 years old
3. Body Mass Index (BMI)=25-40 kg/m2
4. Glycated Hemoglobin (HbA1c) = 5.7-6.4%
5. Blood Pressure (BP) \<160/100
6. Estimated Glomerular Filtration Rate (eGFR) ≥30 ml/min•1.73m2
7. Body weight must be stable (±5 pounds) over the last 3 months.
8. Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization.
9. Hispanic ethic group
10. Willing to adhere to medication regimen for up to 6 months.
11. Male or female, if female, met these criteria:
1. Not pregnant or breast-feeding
2. Negative pregnancy test result at visit 1 (screening)
3. During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period within 1 year must practice appropriate, and effective birth control, either implants or pills, or a vasectomized partner prior to receiving the first dose of study medication
12. Does not suffer from severe claustrophobia
13. No contraindication for Magnetic Resonance Imaging (MRI) (metal plates, screws, shrapnel, pins, or cardiac pacemaker)
Exclusion Criteria:
1. Patients currently on one of the selected therapies
2. Extended diagnoses with Type 2 Diabetes
3. Pregnancy, lactation, women of childbearing age (WOCBA) unwilling to use contraception
4. Known allergy/sensitivity to study drugs or their ingredients
5. Major oncologic diagnosis in the last 5 years
6. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
7. Inability or unwillingness of individual or legal guardian/representative to give written informed consent
8. Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study
9. Myocardial infraction, coronary artery bypass graft surgery, or other major cardiovascular event in the past 60 days
10. Heart transplant recipient or listed for a heart transplant
11. Currently implanted left ventricular assist device
12. Cardiomyopathy based on infiltrative or cumulative hypertrophic obstructive cardiomyopathy or known pericardial constriction
13. Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period
14. Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support within 1 week of screening and during the screening period prior to randomization
15. Implanted cardioverter defibrillator within 3 months prior to screening
16. Cardiac resynchronization therapy
Where this trial is running
San Antonio, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Carolina Solis-Herrera, MD — The University of Texas Health Science Center at San Antonio
- Study coordinator: Carolina Solis-Herrera, MD
- Email: solisherrera@uthscsa.edu
- Phone: 210-567-4900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.